Integrin Signaling Modulation Therapy represents a novel approach targeting the integrin signaling pathway to restore synaptic function, enhance neuroprotection, and modulate microglial phagocytosis in neurodegenerative diseases. Integrins are heterodimeric transmembrane receptors that connect the extracellular matrix to the intracellular cytoskeleton, playing critical roles in cell adhesion, migration, survival, and synaptic plasticity.
The central nervous system expresses multiple integrin heterodimers with distinct functions:
- α5β1 integrin: Primary fibronectin receptor, regulates neuronal migration and synaptic formation
- α6β1/β4 integrins: Laminin receptors, essential for neurite outgrowth and myelination
- αvβ3 integrin: Vitronectin receptor, implicated in synaptic plasticity and memory formation
- α4β1 (VLA-4): Leukocyte integrin mediating immune cell infiltration
- αMβ2 (Mac-1): Microglial integrin regulating phagocytosis
Integrin signaling is perturbed in multiple neurodegenerative conditions:
- Alzheimer's disease: Altered integrin expression on neurons and glia; β1 integrin reductions correlate with synaptic loss
- Parkinson's disease: α-synuclein interacts with integrins to promote microglial activation and neuron-to-neuron propagation
- ALS: Integrin alterations affect neuromuscular junction stability and astrocyte-neuron communication
- β1 integrin stabilization: Promote synaptic spine formation and maintenance
- FAK modulation: Enhance downstream survival signaling (PI3K/Akt, MAPK)
- Actin cytoskeleton remodeling: Restore dendritic spine morphology
- αMβ2 (Mac-1) modulation: Fine-tune microglial clearance of debris and protein aggregates
- Integrin-αvβ3 targeting: Modulate microglial inflammatory response
- α4β1 antagonism: Reduce pathological immune cell infiltration
- Pericyte-integrin signaling: Preserve BBB integrity
| Attribute |
Specification |
| Primary Target |
α5β1, αvβ3, αMβ2 integrins |
| Modality |
Small molecule or antibody |
| Delivery |
Systemic with BBB penetration |
| Patient Population |
Early-to-moderate AD, PD, ALS |
| Dimension |
Score |
Rationale |
| Novelty |
8 |
Integrin targeting in neurodegeneration is underexplored |
| Mechanistic Rationale |
8 |
Integrins link ECM to neuronal survival; documented alterations in AD/PD |
| Root-Cause Coverage |
7 |
Addresses synaptic dysfunction and neuroinflammation |
| Delivery Feasibility |
6 |
BBB penetration remains challenging |
| Safety Plausibility |
7 |
Integrin modulators have shown acceptable profiles in oncology |
| Combinability |
8 |
Synergistic with anti-amyloid, anti-inflammatory approaches |
| Biomarker Availability |
6 |
CSF integrin fragments as potential markers |
| De-risking Path |
7 |
Clear readouts in preclinical models |
| Multi-disease Potential |
9 |
Strong rationale across AD, PD, ALS |
| Patient Impact |
7 |
Addresses fundamental synaptic deficits |
Total Score: 73/100
| Disease |
Coverage Score |
Priority |
| Alzheimer's Disease |
8 |
Primary |
| Parkinson's Disease |
7 |
Secondary |
| ALS |
6 |
Secondary |
| FTD |
5 |
Tertiary |
| Aging |
7 |
Prevention |
- In vitro: Test integrin modulators on neuronal cultures, astrocyte-neuron co-cultures
- In vivo: Use integrin-knockout or transgenic models (e.g., β1 conditional KO)
- Efficacy endpoints: Synaptic marker expression, behavioral testing, microglia morphology
- Phase I: Safety in healthy volunteers (similar to integrin antagonists in oncology)
- Phase II: Proof-of-concept in early AD/PD patients
- Biomarkers: CSF integrin fragments, synaptic PET ligands
- Year 1: Identify lead compounds from integrin modulator libraries
- Year 2: Preclinical GLP toxicology and IND-enabling studies
- Year 3: Phase I clinical trials
- Year 4-5: Phase II efficacy trials with synaptic biomarkers
¶ Risks and Mitigation
| Risk |
Likelihood |
Mitigation |
| Off-target effects |
Moderate |
Selective compound optimization |
| BBB penetration |
High |
Focus on small molecule approaches |
| Immunogenicity |
Low |
Use small molecules over antibodies |
| Integrin redundancy |
Moderate |
Target multiple integrin subtypes |
- Literature review: Deep dive into integrin alterations in AD/PD post-mortem tissue
- Compound screening: Partner with oncology integrin programs for CNS repurposing
- Biomarker development: Establish CSF integrin fragment assay
- Academic collaboration: Connect with integrins-in-CNS researchers